Immuron recruiting patients for ASH trial
19 January, 2015 by Dylan Bushell-EmblingImmuron (ASX:IMC) has enrolled the first patients for a phase II trial of IMM-124E in alcoholic steatohepatitis and arranged to potentially license the drug candidate in alcohol-induced liver toxicity.
Novogen claims brain regeneration breakthrough
16 January, 2015 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a family of compounds with the potential to promote the growth and activity of stem cells in injured parts of the brain.
Low dollar tipped to stimulate biotech investment
15 January, 2015Analyst commentary suggests the devaluation of the Australian dollar during 2014 has left biotech in a good position for investment, as well as a target for takeovers and mergers.
Mesoblast MPCs improve back pain in phase II trial
15 January, 2015 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has presented data from its phase II trial of MPCs in lower back pain and initiated a phase III program on the strength of the results.
Start-up seeks to improve stability of antibodies
15 January, 2015 by Dylan Bushell-EmblingSolvanix, an Australian start-up commercialising a technology to improve the stability and reduce side effects associated with antibody therapies, launched today with $2m in MCRF funding.
Phosphagenics names new CEO
14 January, 2015 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has appointed Dr Ross Murdoch as its new CEO and has received ethics approval for a pilot trial of TPM/Oxycodone in post-herpetic neuralgia.
Join us in our New Year's resolutions to grow the biotech industry
13 January, 2015The time is here to list AusBiotech's New Year's resolutions, which will buoy and grow the Australian biotechnology industry, support your success and ensure 2015 is the best year yet.
CNS establishes US operations
09 January, 2015 by Dylan Bushell-EmblingConsulting company Clinical Network Services (CNS) has established an office in the US to allow it to support clients seeking to engage with the FDA.
Graeme Clark wins Russ Prize for cochlear implant
08 January, 2015 by Dylan Bushell-EmblingProfessor Graeme Clark and four international scientists have jointly won the biennial US$500,000 Russ Prize for their contributions to the developing the cochlear implant.
Inaugural industry report released
11 December, 2014The Australian Industry Report 2014 has been released by the Department of Industry's Office of the Chief Economist. Providing an overview and analysis of the major economic factors affecting Australia's industries, the focus of this year's inaugural report is structural change.
AusBiotech reflects on a year of advocacy and achievement
11 December, 2014For the biotechnology industry and for AusBiotech, the past year has been another action-packed period in policy terms, as well as the year the Australian biotech industry was ranked fourth in the world.
Join the Australian pavilion at the China Medical Equipment Fair
09 December, 2014AusBiotech seeks your expression of interest to join the Australian delegation to the 73rd China International Medical Equipment Fair (CMEF) in May 2015. It is said to be the Asia-Pacific's largest exhibition, with around 2700 exhibitors and 80,000 visitors.
Cochlear appoints two new directors
09 December, 2014 by Dylan Bushell-EmblingCochlear has announced that seasoned executives Alison Deans and Glen Boreham will take on non-executive director roles starting from next year.
GI Dynamics to cut 10% of jobs
09 December, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has revealed a restructuring plan involving cutting 10% of its workforce, including CFO Robert Crane.
Orthocell enters bone repair partnership
08 December, 2014 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has signed a deal to develop bone repair products combining technology from the company and from Bonesupport.
